A medical oncologist at a specialty cancer center discusses their current experiences with using monitoring and MRD tests for their patients. This medical oncologist is most familiar with ctDNA monitoring in NSCLC and CRC patients, as well as some patients with renal or bladder cancer.They expect their use of these technologies to increase in coming years, as they see utility in other cancer types such as breast and even pancreatic. Their current test of choice is Signatera, though they were once a Guardant user, having since found preferences for tumor-informed testing. They expect that increased payer coverage and stronger clinical utility data will expedite test implementation, as they themselves would double their test volumes if prices allowed for it.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.